racemetirosine has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Del Priore, G; Hoffman, S; Noel, MS; Stega, D; Stega, J; Vandell, AG | 1 |
| Del Priore, G; Gartrell, BA; Retter, A; Roach, M; Scher, HI; Sokol, GH | 1 |
2 trial(s) available for racemetirosine and sirolimus
| Article | Year |
|---|---|
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.
Topics: Aged; alpha-Methyltyrosine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Humans; Hyperpigmentation; Male; Melanins; Middle Aged; Neoplasms; Phenytoin; Pilot Projects; Quality of Life; Sirolimus; Survival Analysis | 2020 |
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Humans; Kaplan-Meier Estimate; Male; Methoxsalen; Middle Aged; Neoplasm Recurrence, Local; Phenytoin; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Sirolimus; Tyrosine | 2021 |